Pedro López‐Romero

Novartis (Switzerland) — Switzerland

Medicine · Health Sciences

27h-index3.6kcitations72works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(15), Bone health and osteoporosis research(8), Genetic and phenotypic traits in livestock(7), Chronic Lymphocytic Leukemia Research(6), MicroRNA in disease regulation(5)

Publications72 total

Estimated distribution of malaria cases among children in sub-Saharan Africa by specified age categories using data from the Global Burden of Diseases 2019
Malaria Journal·2023· 36 citedOpen Access
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
Rheumatology and Therapy·2022· 15 citedOpen Access
Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
Annals of the Rheumatic Diseases·2022· 16 citedOpen Access
Étude internationale, observationnelle et prospective chez des patients atteints de PR recevant du baricitinib, des csDMARD ou bDMARD : efficacité à 6 mois et résultats des mesures rapportées par les patients (PRO) de la cohorte européenne
Revue du Rhumatisme·2021
Étude internationale, observationnelle et prospective chez des patients atteints de PR recevant du baricitinib, des csDMARD ou bDMARD (RA-BE-REAL): schéma de l’étude et caractéristiques des patients à l’inclusion
Revue du Rhumatisme·2021
AB0261 A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BARICITINIB, TARGETED SYNTHETIC OR BIOLOGIC DISEASE-MODIFYING THERAPIES (RA-BE-REAL) – STUDY DESIGN AND BASELINE CHARACTERISTICS
Annals of the Rheumatic Diseases·2021· 3 cited
Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN
Arthritis Research & Therapy·2020· 3 citedOpen Access
Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial
Osteoporosis International·2020· 25 citedOpen Access
P204 Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDs
Lara D. Veeken·2020Open Access
Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial
Calcified Tissue International·2020· 9 citedOpen Access
Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDS
Internal Medicine Journal·2020
Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
Bone·2019· 16 cited
FRI0467 THE DISTRIBUTION OF PREVALENT AND INCIDENT VERTEBRAL FRACTURES IN THE TERIPARATIDE VERSUS RISEDRONATE “VERO” CLINICAL TRIAL
Annals of the Rheumatic Diseases·2019Open Access
SAT0102 ASSOCIATION BETWEEN BASELINE HAEMOGLOBIN LEVELS AND RADIOGRAPHIC JOINT DAMAGE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB OR STANDARD OF CARE
Annals of the Rheumatic Diseases·2019· 2 citedOpen Access
Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
Archives of Osteoporosis·2019· 10 cited
Vitamine D Status And 25ohd Serum Levels On The Risk Of Fractures In The Teriparatide Vs Risedronate Vero Trial
Osteoporosis and Sarcopenia·2018Open Access
Patient Characteristics And Fracture Outcomes In Patients Previously Treated With Bisphosphonates In VERO Trial
Osteoporosis and Sarcopenia·2018Open Access
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
Annals of the Rheumatic Diseases·2018· 81 citedOpen Access
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
Clinical Rheumatology·2018· 32 citedOpen Access
Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis
Open Access Rheumatology Research and Reviews·2018· 15 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Piet Geusens(6), Borja Ibáñez(6), Ana Dopazo(6), David L. Kendler(5), Éric Lespessailles(5), Salvatore Minisola(5), Antonio Fernández‐Ortíz(5), Juan C. Garcı́a-Rubira(5), Valentı́n Fuster(5), Benjamín Fernández‐Gutiérrez(5), Inmaculada de la Torre(5), Cristiano A. F. Zerbini(4), Astrid Fahrleitner‐Pammer(4), M. J. Carabaño(4), Pilar Tornero-Esteban(4), Luis Rodríguez‐Rodríguez(4), José Ramón Lamas(4), Fernando Marín(3), Luis Augusto Tavares Russo(3), A. Bagur(3)